Optimax Access

We are thrilled to announce the publication of our latest research in Frontiers in Neurology. This systematic review and network meta-analysis compares the efficacy and tolerability of ublituximab versus other monoclonal antibodies (mAbs) for the treatment of relapsing multiple sclerosis (RMS). Our analysis included data from 15 randomized controlled trials and evaluated key outcomes, such as annualized relapse rates (ARR), confirmed disability progression (CDP), and treatment discontinuation rates. The results highlight: • Ublituximab as one of the most effective treatments for ARR, with statistically significant improvements over placebo. • Comparable efficacy between ublituximab and other leading mAbs, including alemtuzumab, natalizumab, ocrelizumab, and ofatumumab. • Superior safety and tolerability profiles, underscoring the potential of ublituximab as a competitive option for managing RMS. These findings offer valuable insights for clinicians, patients, and policymakers when considering treatment strategies for RMS. This work reflects a collaborative effort involving teams from Optimax Access, Queen Square MS Centre (UCL), Royal Hallamshire Hospital Sheffield, and Neuraxpharm. Special thanks to all authors Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Wallace Brownlee, David Paling, Amir Ansaripour - PhD, and Mehdi Javanbakht. Read the full article here: https://lnkd.in/eybjNnWw #HEOR #HealthEconomics #Neurology #MultipleSclerosis #ResearchPublication

🌟 Breaking into the NHS in England: Insights for Market Access Leaders 🌟 Are you a global market access leader working to support your UK affiliates? Or perhaps you’re navigating the complexities of bringing an innovative health technology to the NHS in England? The NHS is dynamic and ever-evolving, with new structures, decision-makers, and priorities emerging in recent years. Staying informed and strategic is essential to succeed in this unique landscape. 🛠️ Key Strategies for Success 1️⃣ Understand the Landscape • Get familiar with the NHS’s latest frameworks, including Integrated Care Systems (ICSs) and new decision-making bodies. 2️⃣ Engage the Right Stakeholders • Timing is everything—know who to speak to, when, and where in the technology’s lifecycle. 3️⃣ Tailor Your Value Proposition • Highlight how your innovation addresses clinical need, aligns with NHS priorities, and delivers cost-effective solutions. 4️⃣ Navigate Market Access Pathways • Explore NICE appraisals, early access schemes, and other routes to get your product into the NHS. 5️⃣ Address Challenges Proactively • Be prepared to overcome hurdles like budget constraints, equity of access, and evolving local priorities. The NHS offers incredible opportunities for impactful health innovations. By understanding the challenges and adopting the right strategies, you can make a meaningful impact on patient outcomes while achieving commercial success. 💬 What’s been your biggest challenge in navigating the NHS? Let’s connect and discuss! #MarketAccess #HealthcareInnovation #NHS #Pharma #MedicalDevices #Biopharma #HEOR #HealthEconomics

Driving Strategic Decisions: Early Health Economics Models for Pharma, Biotech, and MedTech companies💡 For pharmaceutical, biotech, and MedTech companies, early health economics models are essential tools for shaping innovation and driving success. These models evaluate the cost-effectiveness of early-stage interventions using clinical trial data, empowering you to: ✅ Define Pricing Strategies ✅ Identify Key Drivers of the Value Proposition ✅ Select Target Populations ✅ Make Go/No-Go Decisions 📊 Early models not only assess cost-effectiveness but also uncover critical data gaps and inform research priorities. By exploring uncertainty in model structures and parameters, they deliver actionable insights that enhance ROI and streamline R&D. As your technology advances, early models evolve into comprehensive frameworks for HTA submissions, supporting a smooth transition from development to market access. If you'd like to discuss your case with us, feel free to book a no obligation call here: https://lnkd.in/e628phSJ #HEOR #reimbursement #costeffectiveness #pharmaceuticals #HTA #marketacces #HealthEconomics #earlymodel

🚀 Empowering Small and Midsize Biopharma: Driving the Next Wave of Innovation 🚀 While large biopharma firms continue to invest heavily in R&D, it’s the small and midsize companies that are truly transforming the landscape. These agile players are expected to grow at a faster pace than their larger counterparts, holding a major share of the clinical trials and drug-development pipeline. Despite their size, these companies often face unique challenges like limited resources, lean infrastructure, and the pressure to rapidly scale. But their adaptability allows them to take bold steps—making a difference in fields such as oncology, rare diseases, and cell and gene therapies. 🏥 Collaboration is Key: By partnering with the right teams, small biopharma can bridge data gaps, optimize trial designs, and effectively communicate their innovations to regulators, payers, and healthcare providers. This approach not only supports successful product launches but also ensures that critical therapies reach the patients who need them most. At Optimax Access, we’re passionate about supporting these dynamic companies on their journey, helping them navigate the path from innovation to market success. #BiopharmaInnovation #ClinicalResearch #HEOR #MarketAccess #PatientCenteredCare #SmallBiopharma #HealthEconomics

🌟 What is the EU Joint Clinical Assessment (JCA) and How Will It Transform Pharma and MedTech in Europe? 🌍 In January 2022, the EU enacted the Health Technology Assessment Regulation (HTAR), paving the way for the Joint Clinical Assessment (JCA). This milestone aims to standardize clinical assessments across the EU, reduce duplication, and enhance patient access to innovative therapies. Starting January 2025, cancer medicines and ATMPs will require a JCA, with orphan medicines following in 2028 and all new medicines by 2030. While this simplifies certain processes, local HTAs will still play a critical role in reimbursement decisions. 🚀 Challenges for Pharma & MedTech: - Navigating diverse national requirements. - Managing complex PICO frameworks. - Limited direct interaction with assessors. At Optimax Access and IGES group, we help manufacturers overcome these hurdles. With many successful HTA submissions and expertise in oncology and rare diseases, we ensure your value proposition is robust and ready for EU and national markets. ✅ Need support with your JCA strategy, evidence synthesis, or dossier development? Let’s talk! 🔗 Read more about the JCA and how we can help: https://lnkd.in/eu2j9Eq4 #HealthTechnologyAssessment #JCA #Pharma #MedTech #Innovation #HTA #OptimaxAccess #EUHealthcare #EvidenceBasedDecisionMaking

Team Optimax Access wishes you all a Happy Thanksgiving!

PharmEconix was one of the main conversation topics we had at #ISPOR Europe 2024. We were always thrilled about the interest and positive feedback on our comprehensive HEOR platform. #HEOR #MarketAccess #PharmEconix

Our poster at #ISPOREurope, titled “The Impact of Delayed Treatment in Patients with Noncirrhotic Non-Alcoholic Steatohepatitis (NASH) with Moderate to Advanced Fibrosis” had great interest this morning. 
You can find our team at booth 620 throughout the event in case you couldn’t make it to the discussion or to simply connect.
 Mehdi Javanbakht (Ph.D.) Amir Ansaripour - PhD #NASH #MASH #HealthEconomics #ModelingExcellence #NICEsubmission #LiverDisease #OptimaxAccess #ISPOR #ISPOREurope2024 ISPOR—The Professional Society for Health Economics and Outcomes Research

ISPOR Europe 2024 has started with a record number of 6300 attendees! You can find our team members Amir Ansaripour - PhD, Mehdi Javanbakht (Ph.D.) and Santoke Naal at booth 620. ISPOR—The Professional Society for Health Economics and Outcomes Research #ISPOR #ISPOREurope2024 #ISPOREurope #HEOR #MarketAccess

One of the posters we'll be presenting next week at the ISPOR Europe Conference will focus on #NASH and #MASH:, "The Impact of Delayed Treatment in Patients with Noncirrhotic Non-Alcoholic Steatohepatitis (NASH) with Moderate to Advanced Fibrosis."   This work highlights our expertise in modeling complex conditions like NASH, where the timing of treatment initiation can significantly impact patient outcomes. By examining the effects of delayed treatment, we’re shedding light on the critical decisions that patients, clinicians, and payers face in managing progressive liver diseases.   Our team has a strong track record in advanced modeling techniques and health economics evaluations for challenging disease areas. We’re proud to be pushing the boundaries of evidence generation for better healthcare decision-making.   If you're attending, come by to booth 620 and let’s connect! We’d love to discuss the implications of our findings and how our expertise in complex modeling could support your projects.   #HealthEconomics #ModelingExcellence #NICEsubmission #PharmaResearch #LiverDisease #HealthcareInnovation #OptimaxAccess #ISPOR #ISPOREurope2024 ISPOR—The Professional Society for Health Economics and Outcomes Research